Raptor Pharmaceutical Inc. and DaVita Clinical Research Launch Screening Program to Identify Patients With Late Onset Nephropathic Cystinosis
Published: Oct 23, 2013
NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research® (DCR®) (NYSE:DVA) today announced a collaboration to screen blood samples from patients with end-stage renal disease (ESRD) in an effort to identify patients with unrecognized late-onset nephropathic cystinosis.
Help employers find you! Check out all the jobs and post your resume.